Bristol-Myers Squibb Company
64.41USD
-0.2800 (-0.43%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 46.2B | 45.0B | 48.3B | 48.2B | 49.8B | 48.1B |
| Q1 | 11.6B | 11.3B | 11.9B | 11.2B | 11.5B | — |
| Q2 | 11.9B | 11.2B | 12.2B | 12.3B | 13.0B | — |
| Q3 | 11.2B | 11.0B | 11.9B | 12.2B | 12.7B | — |
| Q4 | 11.4B* | 11.5B* | 12.3B* | 12.5B* | 12.7B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.95 | 3.86 | -4.41 | 3.46 | 6.95 | 6.56 |
| Q1 | .590 | 1.07 | -5.89 | 1.20 | 1.31 | — |
| Q2 | .660 | .990 | .830 | .640 | 1.62 | — |
| Q3 | .750 | .930 | .600 | 1.08 | 1.73 | — |
| Q4 | .942* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .848* |
| .036* |
| .533* |
| 1.59 |
| — |